Metabolic Effects of the Incretin Mimetic Exenatide in the Treatment of Type 2 Diabetes

por Schnabel, Catherine A, Wintle, Matthew, Kolterman, Orville
Publicado 2006

Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92‐Gene Assay

por Raghav, Kanwal, Overman, Michael, Poage, Graham M., Soifer, Harris S., Schnabel, Catherine A., Varadhachary, Gauri R.
Publicado 2020

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer

por Schroeder, Brock, Zhang, Yi, Stål, Olle, Fornander, Tommy, Brufsky, Adam, Sgroi, Dennis C., Schnabel, Catherine A.
Publicado 2017

Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer

por Foldi, Julia, Tsagianni, Anastasia, Salganik, Max, Schnabel, Catherine A., Brufsky, Adam, van Londen, G. J., Pusztai, Lajos, Sanft, Tara
Publicado 2023

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study

por Buus, Richard, Sestak, Ivana, Kronenwett, Ralf, Ferree, Sean, Schnabel, Catherine A., Baehner, Frederick L., Mallon, Elizabeth A., Cuzick, Jack, Dowsett, Mitch
Publicado 2021

Molecular classification of cancer with the 92-gene assay in cytology and limited tissue samples

por Brachtel, Elena F., Operaña, Theresa N., Sullivan, Peggy S., Kerr, Sarah E., Cherkis, Karen A., Schroeder, Brock E., Dry, Sarah M., Schnabel, Catherine A.
Publicado 2016

Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma

por Overman, Michael J., Soifer, Harris S., Schueneman, Aaron Joel, Ensor, Joe, Adsay, Volkan, Saka, Burcu, Neishaboori, Nastaran, Wolff, Robert A., Wang, Huamin, Schnabel, Catherine A., Varadhachary, Gauri
Publicado 2016

Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study

por Sgroi, Dennis C., Treuner, Kai, Zhang, Yi, Piper, Tammy, Salunga, Ranelle, Ahmed, Ikhlaaq, Doos, Lucy, Thornber, Sarah, Taylor, Karen J., Brachtel, Elena, Pirrie, Sarah, Schnabel, Catherine A., Rea, Daniel, Bartlett, John M. S.
Publicado 2022

Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma

por Nunes, Raquel, Sella, Tal, Treuner, Kai, Atkinson, Jennifer M., Wong, Jenna, Zhang, Yi, Exman, Pedro, Dabbs, David, Richardson, Andrea L., Schnabel, Catherine A., Sgroi, Dennis C., Oesterreich, Steffi, Cimino-Mathews, Ashley, Metzger, Otto
Publicado 2021

Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study

por Sgroi, Dennis C., Chapman, Judy-Anne W., Badovinac-Crnjevic, T., Zarella, Elizabeth, Binns, Shemeica, Zhang, Yi, Schnabel, Catherine A., Erlander, Mark G., Pritchard, Kathleen I., Han, Lei, Shepherd, Lois E., Goss, Paul E., Pollak, Michael
Publicado 2016

Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study

por Bartlett, John M.S., Sgroi, Dennis C., Treuner, Kai, Zhang, Yi, Piper, Tammy, Salunga, Ranelle C., Ahmed, Ikhlaaq, Doos, Lucy, Thornber, Sarah, Taylor, Karen J., Brachtel, Elena F., Pirrie, Sarah J., Schnabel, Catherine A., Rea, Daniel W.
Publicado 2022

Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker

por Sgroi, Dennis C., Carney, Erin, Zarrella, Elizabeth, Steffel, Lauren, Binns, Shemeica N., Finkelstein, Dianne M., Szymonifka, Jackie, Bhan, Atul K., Shepherd, Lois E., Zhang, Yi, Schnabel, Catherine A., Erlander, Mark G., Ingle, James N., Porter, Peggy, Muss, Hyman B., Pritchard, Katherine I., Tu, Dongsheng, Rimm, David L., Goss, Paul E.
Publicado 2013